Пожалуйста, подождите, мы загружаем данные графика
Novo Nordisk A/S сообщество
About Novo Nordisk A/S
What is Novo Nordisk A/S?
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is 3 186,73 ₽, with a 24-hour trading volume of 28,26B ₽. The asset's market cap is 14,11T ₽, after moving 0.43% in the last day.
Tokenized Novo Nordisk A/S is trading at 3 249,2 ₽, with a tokenized market cap of 2,39B ₽ and a 24-hour trading volume of 99,26M ₽. The tokenized asset has moved 0.86% in the past 24 hours.